Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity

John J. Suschak\textsuperscript{a}, James A. Williams\textsuperscript{b}, and Connie S. Schmaljohn\textsuperscript{a}

\textsuperscript{a}U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA; \textsuperscript{b}Nature Technology Corporation, Lincoln, NE, USA

\textbf{ABSTRACT}
A major advantage of DNA vaccination is the ability to induce both humoral and cellular immune responses. DNA vaccines are currently used in veterinary medicine, but have not achieved widespread acceptance for use in humans due to their low immunogenicity in early clinical studies. However, recent clinical data have re-established the value of DNA vaccines, particularly in priming high-level antigen-specific antibody responses. Several approaches have been investigated for improving DNA vaccine efficacy, including advancements in DNA vaccine vector design, the inclusion of genetically engineered cytokine adjuvants, and novel non-mechanical delivery methods. These strategies have shown promise, resulting in augmented adaptive immune responses in not only mice, but also in large animal models. Here, we review advancements in each of these areas that show promise for increasing the immunogenicity of DNA vaccines.

\textbf{Introduction}

The constant emergence, and re-emergence, of known and novel pathogens challenges researchers to develop new vaccination technologies that allow for the rapid development of safe and effective vaccines. Nucleic acid (DNA and RNA) vaccines have characteristics that meet these challenges, including ease of production, scalability, consistency between lots, storage, and safety. DNA vaccine technology usually is based on bacterial plasmids that encode the polypeptide sequence of candidate antigens. The encoded antigen is expressed under a strong eukaryotic promoter, yielding high levels of transgene expression.\textsuperscript{1} Inclusion of transcriptional enhancers, such as Intron A, enhance the rate of polyadenylation and nuclear transport of messenger RNA (mRNA).\textsuperscript{2} The vaccine plasmids are generally produced in bacterial culture, purified, and then used to inoculate the host.

Modern DNA vaccine design generally relies on synthesis of the nucleic acid and possibly one-step cloning into the plasmid vector, reducing both the cost and the time to manufacture. Plasmid DNA is also extremely stable at room temperature, reducing the need for a cold chain during transportation. Vaccination with DNA plasmid removes the necessity for protein purification from infectious pathogens, improving safety. Furthermore, DNA vaccination has an excellent safety profile in the clinic, with the most common side effect being mild inflammation at the injection site.\textsuperscript{3} Importantly, DNA vaccines provide a safe, non-live vaccine approach to inducing balanced immune responses, as the in vivo production of antigen allows for presentation on both class I and class II major histocompatibility complex (MHC) molecules (Fig. 1). This elicits antigen specific antibodies,\textsuperscript{4} as well as cytotoxic T lymphocyte responses (CTL),\textsuperscript{5} something that remains elusive in most non-live vaccines. DNA vaccines have also demonstrated the ability to generate follicular T helper populations,\textsuperscript{6} which are critical for the induction of high quality antigen-specific B cell responses.\textsuperscript{7}

DNA vaccination has proven successful in several animal models for preventing or treating infectious diseases, allergies, cancer, and autoimmunity.\textsuperscript{8–12} The early success of small animal studies led to several human clinical trials. However, the protective immunity observed in small animals and non-human primates was not observed in human studies when DNA vaccines were administered alone by needle delivery. Like the more conventional protein-based vaccines, DNA can be delivered by a variety of routes, including intramuscular (IM), intradermal (ID), mucosal, or transdermal delivery. Because DNA plasmids must enter host cell nuclei to be transcribed into mRNA, the early failure of DNA vaccines to elicit strong responses in humans was largely due to their delivery by needle injection, which deposits the DNA in intracellular spaces, rather than within cells. Improved delivery technologies, such as intramuscular or intradermal electroporation, have been used to facilitate transport of DNA into cells, resulting in much better immunogenicity in both clinical and non-clinical studies.\textsuperscript{13–19} In one study, electroporation-enhanced DNA vaccination resulted in increased polyfunctional antigen-specific CD8+ T cells in patients receiving a HPV DNA vaccine expressing the E6 and E7 genes of HPV16 and HPV18 respectively.\textsuperscript{20} The
The use of liposomes as a carrier molecule has become a popular DNA vaccine delivery method as liposomes not only enhance transfection efficiency, but also have an adjuvant effect. Liposomes are spherical vesicles composed of phospholipids and cholesterol arranged into a lipid bilayer, allowing for fusion with cellular lipid membranes. DNA plasmid can be either bound to the liposome surface, or encased within the hydrophobic core of the liposome. This facilitates delivery of the DNA vaccine plasmid into the cells. Importantly, lipid vesicles can be formulated as either unilamellar or multilamellar. Multilamellar vesicles allow for sustained delivery of vaccine over an extended period of time. While the use of liposomes for IM injection has resulted in some reactogenicity issues, liposome/DNA vaccine complexes have demonstrated an immunological benefit. IM injection of a liposome/influenza nucleoprotein formulation increased antibody titers 20-fold compared with vaccine alone. Boosting of antibody titers did not diminish the cytotoxic T cell response. Likewise, inclusion of a liposome formulation in a P. falciparum vaccine enhanced the IFN-γ production. An ensuing human trial involving DNA plasmids encoding the influenza H5 HA, nucleoprotein, and M2 genes reported cellular immune response rates and antibody titers comparable to that of the currently available inactivated protein-based H5 vaccines. Additionally, liposomes have shown promise as a candidate for delivery of DNA vaccines to mucosal tissue. A recent study demonstrated that vaccination with liposome encapsulated influenza A virus M1 induced both humoral and cellular immune responses that protected against respiratory infection. Liposomes have also been shown to be an effective delivery method for intranasal DNA vaccination, conferring protective immune responses against infection.

DNA vaccine delivery can also be accomplished through the use of biodegradable polymeric micro- and nanoparticles consisting of amphiphilic molecules between 0.5–10 μm in size. Similar to loading of DNA plasmid on liposomes, plasmid molecules can be either encapsulated or adsorbed onto the surface of the nanoparticles. These particles function as a carrier system, protecting the vaccine plasmid from degradation by extracellular deoxyribonucleases. In addition to shielding plasmid DNA from nucleases, micro- and nanoparticles promote the sustained release of vaccine instead of the bolus type of delivery characteristic of larger submicrometer complexes. High molecular weight cationic polymers have proven significantly more effective than cationic liposomes in aggregating DNA vaccine plasmid. Plasmid DNA immobilized within biodegradable chitosan-coated polymeric microspheres (ranging from 20 to 500 μm) can induce both mucosal and systemic immune responses. Microspheres may be delivered either by the oral or intraperitoneal route, allowing for direct transfection of dendritic cells (DC), thereby increasing DC activation. The benefits of microsphere formulations have been shown in mice, non-human primates, and humans against a wide range of diseases including hepatitis B, tuberculosis, and cancer. These results suggest that microparticle-based delivery systems are capable of significantly improving DNA vaccine immunogenicity, and boosting cellular and humoral immune responses.

The use of liposomes or nanoparticles appears to be safe and well tolerated in clinical studies. Microparticle-based delivery
systems can increase gene expression, as well as, DNA vaccine immunogenicity. Although many of the earliest carrier formulations did not show a significant clinical benefit, more recent studies highlighted herein yielded promising clinical data. As microparticles can be prepared with significant structural diversity (size, surface charge, lipid content), they offer considerable flexibility of vaccine formulation. This allows for optimization of the vaccine based on the specific needs of the clinician.

**Molecular adjuvants**

Another approach that has been effective in increasing DNA vaccine immunogenicity is the use of “vaccine cocktails” containing the DNA vaccine as well as plasmids encoding adjuvanting immunomodulatory proteins. Plasmid DNA contains unmethylated deoxycytidylate-phosphate-deoxyguanylate (CpG) motifs that function as a “built in” adjuvant. Molecular adjuvant plasmids expressing cytokines, chemokines, or co-stimulatory molecules may be co-administered with the antigenic DNA vaccine plasmid. Cells transfected by molecular adjuvant plasmids secrete the adjuvant into the surrounding region, stimulating both local antigen presenting cells (APC) and cells in the draining lymph node. This results in durable, but low level, production of immune modulating cytokines that can tailor the immune response toward a more desirable outcome without the concerns of a systemic cytokine storm. While human data are limited, a wide range of inflammatory and helper T cell cytokines have been studied, in conjunction with DNA vaccination, in small animal models. In particular, we have highlighted a few of the most prominent molecular adjuvants with demonstrated ability to increase DNA vaccine immunogenicity. A more comprehensive list of molecular adjuvants is included in Table 1.

**Plasmid-encoded cytokines**

Cytokines are a class of immunoregulatory proteins that affect the behavior of other cells, and are critical for immune cell signaling. Cytokine-encoding genes can be delivered either as a separate plasmid, or as additional genes encoded within the antigen containing plasmid. The most extensively studied molecular adjuvant is Interleukin-2 (IL-2). IL-2 plays an essential role in the immune response by promoting the differentiation of naive T cells into effector T cells, as well as driving the generation of memory T cell pools. It is also required for the proliferation of Natural Killer (NK) cells. Inclusion of IL-2 has resulted in improved immunogenicity for HIV, influenza, and SARS-CoV anti-viral DNA vaccines. Interestingly, a therapeutic vaccine encoding for the BCR/ABL-pIRES genes of myeloid leukemia and IL-2 also demonstrated enhanced immune responses, suggesting that IL-2 molecular adjuvants have the capability of alleviating the symptoms of chronic infection.

Similar to IL-2, IL-15 is a cytokine that induces NK and T cell proliferation. IL-15 is necessary for the generation of primary antigen-specific CD4⁺ and CD8⁺ T cell responses. It also plays a substantial role in establishment of memory CD8⁺ T cell populations. Results of small animal studies suggest that the adjuvant effect of IL-15 is most potent when delivered in tandem with other cytokines. For example, a synergistic effect was seen when IL-15 and IL-21 were co-delivered with a DNA vaccine against Toxoplasma gondii infection. Additionally, sequential administration of IL-6, IL-7, and IL-15 genes augmented long-term CD4⁺ T cell memory responses to a foot and mouth disease DNA vaccine. Therefore, depending on the antigen, it may be necessary to deliver IL-15 in combination with other molecular adjuvants. Notably, a study in rhesus macaques suggests that delivery of an IL-15 encoding DNA vaccine itself resulted in increased proliferation of NK and T cells, with no adverse effects. Another recent study demonstrated that co-vaccination of rhesus macaques with SIV pol plasmid and HIV env plasmid plus IL-15 allowed for faster control of viremia than the group not formulated with IL-15. Moreover, macaques vaccinated with IL-15 exhibited increased T cell proliferation compared with those receiving the antigen plasmid alone, suggesting that IL-15 has a robust effect on T cell memory responses.

IL-12 is another pro-inflammatory cytokine secreted by both dendritic cells and monocytes. IL-12 plays an integral role in shaping the innate and adaptive immune responses to infection. IL-12 signaling supports the secondary expansion of activated T helper 1 (Th1) cells, resulting in high levels of cytokines such as IFN-γ, IL-2, and TNF-α.

| Molecular Adjuvant | Molecule Type | Animal Model | Adaptive Response Effect | References |
|--------------------|---------------|--------------|--------------------------|------------|
| CD40L | Co-Stimulatory | Mice | Humoral | 163 |
| CD80/86 | Co-Stimulatory | Mice, NHP | Humoral | 164 |
| GM-CSF | Cytokine | Mice | Humoral | 163 |
| ICAM-1 | Co-Stimulatory | Mice | Cellular | 164 |
| IFN-γ | Cytokine | Mice, NHP | Cellular | 165,166 |
| IL-2 | Cytokine | Mice | Humoral | 166,167 |
| IL-4 | Cytokine | Mice, NHP | Humoral | 165,166 |
| IL-7 | Cytokine | Mice | Humoral | 165,166 |
| IL-8 | Chemokine | Mice | Humoral | 166,170 |
| IL-10 | Cytokine | Mice | Humoral | 166,171 |
| IL-12 | Cytokine | Mice, NHP | Humoral | 166,172 |
| IL-15 | Cytokine | Mice, NHP | Humoral | 166,173 |
| IL-18 | Cytokine | Mice | Humoral | 166,174 |
| M-CSF | Cytokine | Mice | Humoral | 169 |
| MIP-1α | Chemokine | Mice | Humoral | 169 |
| RANTES | Chemokine | Mice | Humoral | 169,170 |
of antigen-specific CD8+ T cells, and the expression of cytotoxic mediators such as interferon-γ (IFN-γ), granzyme B, and perforin.12,28 IL-12 was the first cytokine to be evaluated for use as a molecular adjuvant, and several studies have shown that inclusion of IL-12 expression plasmids within the vaccine formulation enhances Th1 immune responses.87-95 Vaccination of mice with a bicistronic plasmid expressing IL-12 and Yersinia pestis resulted in increased mucosal IgA and serum IgG, providing significantly higher levels of protection against challenge than antigen-only groups.96 Studies in rhesus macaques have shown similar increases in DNA vaccine immunogenicity. Co-vaccination with SIV gag and IL-12 allowed for dose sparing,97 as well as increased breadth of T cell responses.89,99,100 Additionally, multiple human clinical studies using vaccines adjuvanted with IL-12 have proven safe100 and highly immunogenic, yielding high level CD4+ and CD8+ T cell responses.87,101,102 Furthermore, inclusion of IL-12 expression plasmids can improve weakly immunogenic vaccines. A recent clinical study demonstrated that addition of IL-12 improved the immunogenicity of a Hepatitis B DNA vaccine, resulting in increased vaccine immunogenicity, as well as sustained memory T cell responses.103

The final immunomodulatory cytokine that has received considerable focus as a molecular adjuvant is granulocyte-macrophage colony stimulating factor (GM-CSF). GM-CSF recruits antigen presenting cells to the vaccination site and promotes DC maturation.104 It has been successfully used in multiple DNA vaccines.105-107 Plasmid-encoded GM-CSF, when co-delivered with a rabies virus DNA vaccine in mice, resulted in increased CD4+ T cell responses, antibody production, and protection from lethal viral challenge.108 Likewise, a bicistronic DNA vaccine encoding HIV-1 gp120 and GM-CSF recruited inflammatory cellular infiltrates and elicited a potent CD4+ T cell response.109 However, the benefit of GM-CSF molecular adjuvants remains unclear. Recent studies have shown that co-administration of GM-CSF plasmid with an antigen-encoding DNA vaccine can have deleterious effects. Co-delivery of GM-CSF suppressed the response to a DNA vaccine encoding Dengue virus type 1 and type 2, and also failed to improve the response elicited by a Hepatitis C vaccine.110 Furthermore, inclusion of plasmid GM-CSF provided minimal adjuvant effect when co-administered with a malaria DNA vaccine in rhesus macaques.111 Likewise, GM-CSF had no clear effect on T cell responses in patients receiving a melanoma DNA vaccine.112 One possible explanation for these results is that high levels of GM-CSF can expand myeloid suppressor cell populations, and suppress the generation of adaptive immune responses. Alternatively, the lack of improved immunogenicity seen in clinical trials may be due to the relative lack of GM-CSF receptors on rhesus and human APC compared with murine cells.113 While no specific adverse effects have been reported, the use of GM-CSF as an adjuvant may require some fine-tuning, particularly if GM-CSF expression levels must be considered with regards to immunosuppression.

In addition to cytokine-encoding plasmids, several other methods for increasing DNA vaccine immunogenicity exist. The increased understanding of immune signaling pathways has led to the development of adjuvant plasmids encoding adhesion molecules, chemokines, costimulatory molecules, and Toll-like receptor (TLR) ligands. These molecular adjuvants have had some success in small animal models. For example, the innate immune signaling molecule TRIF increased the antibody response generated by a swine fever virus DNA vaccine.114 Moreover, TRIF increased the protective activity of an influenza HA-encoding DNA vaccine.115 Similar results were seen in studies encoding the dsRNA receptors MDA5 and RIG-I.116,117 Additionally, antigen-fusion constructs, whereby the antigen of interest is linked to a “carrier protein,” can increase the immune visibility of the vaccine, and enhance DNA vaccine potency.118-120

A major advantage of DNA vaccination is the ability of multiple molecules such as molecular adjuvants to be inserted into the plasmid. Unlike the addition of recombinant cytokines, costimulatory molecules, and TLR ligands, which have a limited duration due to the short half-life of recombinant protein in vivo, molecular adjuvant-encoding plasmids will express protein for the same duration as the antigen, stimulating the immune system for a greater length of time. This can be done without fear of eliciting a cytokine storm, as generation of the adjuvanting signal will be localized to the site of vaccination. Of note, homologous recombination between plasmid-encoded cytokines and the host gene sequence does not appear to be a significant concern, as multiple studies have shown that only extrachromosomal plasmid DNA has been identified following intramuscular injection.121,122 Furthermore, many current plasmids have been-codon optimized to improve gene expression in mammalian cells. This has resulted in changes to the cytokine gene sequence, limiting the possibility for homologous recombination and/or integration. Molecular adjuvants therefore show great promise for both increasing immunogenicity and extending the longevity of the immune response.

**Improvements in DNA plasmid design**

Plasmid DNA vectors contain functional elements, such as the origin of replication and selection markers, that are only required during the prokaryotic growth process in *E. coli*. These “bacterial region” elements (Fig. 2) are no longer needed once cell culture is halted, and may have a negative effect on vaccine stability, uptake, and efficacy. Additionally, these elements can pose safety concerns, particularly if widely used antibiotic resistance markers are horizontally transmitted to host enteric bacteria populations.123,124

These concerns have been addressed by development of small bacterial RNA-based antibiotic free selection markers.124,125 Noncoding RNA markers are preferable to protein markers since proteins, like antibiotic resistance markers, can be expressed in the host organism after vector transfection, or horizontally transmitted to host bacteria. Noncoding RNA markers are also very small (< 200 basepairs) which decreases the overall vector size; this is advantageous since vector transfection efficiency is inversely related to vector size.126-128 Perhaps because smaller vectors are more resistant to delivery associated shear forces129 and may have improved nuclear localization since they are more motile in the cytoplasm.130 Additionally, some bacterial region protein marker genes have been shown to dramatically reduce vector expression. For
example, the TN5 derived NPT-II kanamycin resistance marker (kanR) gene in the pVAX1 vector bacterial region significantly reduces transgene expression. Three groups have demonstrated that pVAX1 bacterial region mediated repression of transgene expression can be alleviated by replacement of the kanR gene with either a tRNA RNA selection marker, the RNA-OUT antisense RNA selection marker, or the endogenous pUC origin RNAI antisense RNA selection marker. Consistent with this, removal of the pVAX1 bacterial region in a minicircle vector improved humoral and cellular immune responses up to 3-fold compared with a pVAX1 vector control. DNA vaccine vectors with dramatically higher transgene expression have recently been developed through identification of novel bacterial region and eukaryotic region vector configurations. Pioneering work by Mark Kay’s laboratory at Stanford University demonstrated that bacterial regions larger than 1 kbase silenced transgene expression in quiescent tissue such as the liver, likely due to untranscribed bacterial region mediated repression of transgene repression the bacterial region is within the transcription unit and inactivates the promoter. Minicircle vectors, in which the bacterial region is removed by the action of a phage recombinase during production, alleviated this silencing. However, production of minicircle vectors is low yield and poorly scalable due to the required in vivo or in vitro recombination during manufacture. In an effort to create alternative short bacterial region vectors that could be efficiently manufactured, the Mini-Intronic Plasmid (MIP) and Nanoplasmid™ vector plasmid platforms were developed. MIP vectors incorporate a RNA-OUT selection marker-pUC origin bacterial region within a 3’ UTR intron. In this configuration the bacterial region is within the transcription unit and the downstream polyA signal is linked to the eukaryotic promoter without an intervening selection marker or replication origin. Nanoplasmid™ vectors are RNA-OUT selection marker vectors in which the large pUC bacterial replication origin is replaced by a small R6K bacterial replication origin. In this configuration, the < 500 basepair (bp) bacterial region separates the polyA signal and the eukaryotic promoter. Unlike minicircles, both MIP and Nanoplasmid™ RNA-OUT selection vectors can be efficiently manufactured in gram/liter yields without antibiotic selection. As expected, both vector platforms alleviate gene silencing in quiescent tissues similarly to minicircle vectors. However, unexpectedly both MIP and Nanoplasmid™ vectors dramatically improve overall gene expression up to 10-fold compared with plasmid and minicircle vectors in quiescent (liver) and non-quiescent tissues. The improved expression level after ID and IM delivery has application to improve DNA vaccination since increased expression level is correlative with improved humoral and cellular immune response.

Another approach to improve DNA vaccines is to engineer the vector to increase innate immune activation. DNA vaccines are potent triggers of innate immunity. Various studies have determined several innate immune pathways are activated by DNA vaccination (Fig. 2). Most of the intrinsic adjuvant effect of DNA is mediated by cytoplasmic innate immune receptors that nonspecifically recognize B DNA and activate Sting or Inflammasome mediated signaling. Unlike CpG sequences specific for TLR9 activation may also be important for priming CD8 T cell responses. Along these lines, DNA vaccine vectors may be sequence modified to introduce immunostimulatory xxCGxx motifs into the vector to increase innate immune activation. This approach has been used to improve DNA vaccine immunogenicity, but the results are variable. Some of the variability may be due to unintended inhibition of the eukaryotic promoter expression resulting from integration of CpG motifs into non-permissive sites in the vector. As well, certain DNA delivery methods may not transfer DNA to the endosome as effectively as other deliveries (e.g. liposomes), preventing unmethylated CpG interaction with, and activation of, TLR9. Part of the complexity is that optimal TLR9 activating xxCGxx motifs are species-specific; different xxCGxx agonist motifs differentially modulate the immune response and many xxCGxx motifs are immunosuppressive.

An alternative strategy is to encode immunostimulatory RNA within the plasmid to increase innate immune activation. This approach has the potential advantage that additional innate immune pathways not normally stimulated by DNA alone are activated, resulting in polyvalent activation of multiple innate immune pathways to enhance immune activation. Like TLR9 for DNA, several innate immune TLRs for RNA are endosomal. Activation of these receptors requires motif introduction into an expressed RNA, as well as cytoplasmic RNA shunting into the endosome by autophagy. For example, 3’UTR
incorporation of a 20 bp immunostimulatory ssRNA encoding D-type CpG upstream of a 28 bp hairpin dsRNA resulted in a 4-fold increase in antigen reactive IgG titers,\(^{151}\) and a 2-fold increase in IFN-γ secreting CD4\(^+\) and CD8\(^+\) T cells.\(^{152}\) Moreover, several RNA-sensing innate immune receptors such as RIG-I, MDA5 and DDX3 are cytoplasmic.\(^{143}\) DNA vaccine expression can be used to target these receptors directly, without autophagy. Of these, RIG-I is of particular interest since RIG-I agonists have demonstrated adjuvant properties to improve the humoral response,\(^{153}\) humoral and CD4\(^+\) T cell response,\(^{154,155}\) and CD8\(^+\) T cell response\(^{156}\) to co-administered antigens.\(^{156}\) In addition, RIG-I is ubiquitously expressed in most tissues (expression of TLRs typically is restricted to immune cell subtypes) and certain RIG-I agonists that can be expressed in DNA vaccines (e.g., a blunt dsRNA with a 3′ triphosphate) are structurally conserved between humans and mice. A DNA vaccine vector that co-expresses with antigen a RIG-I dsRNA agonist in a vector backbone encoded RNA Polymerase III transcription unit (Fig. 2) enhanced the humoral and CD8\(^+\) T cell response after DNA vaccination.\(^{117}\)

DNA vaccines encoding immunostimulatory sequences that selectively improve CTL responses to encoded antigen may have niche application in vaccines for intracellular pathogens or cancer. Innovations that increase transgene expression may be used to improve the performance of immunomodulatory molecular adjuvant plasmids, in addition to traditional antigen expressing DNA vaccine plasmids. Collectively, vector design innovations that improve transgene expression level and innate immune activation are complementary to improved mechanical and non-mechanical DNA vaccine delivery platforms. Combining improved vectors with liposome or polymeric particle non-mechanical delivery, or with needle free injector device delivery, has the potential to increase immunogenicity with these well tolerated, safe, delivery platforms.

**Conclusion**

While DNA vaccination provides several advantages over more conventional vaccination strategies, further optimization is necessary before it becomes the predominant strategy over more conventional vaccination strategies, further optimization is necessary before it becomes the predominant strategy. Despite initial setbacks, significant progress has been made in overcoming the problem of low immunogenicity in humans. A clearer understanding of the immune mechanisms governing DNA vaccine immunogenicity has illuminated several pathways that may be useful in further improving DNA vaccine efficacy. A large catalog of cytokines, chemokines, adhesion molecules, and transcription factors are in the process of being tested as molecular adjuvants, although it is likely that each will need to be carefully assessed for safety and tolerability. Likewise, continued development of vaccine delivery methods appears promising. New formulations exploiting sustained vaccine delivery methods, such as slow-releasing micropatches or multilamellar vesicles, are on the horizon. The strong appeal of needle-free injection and mucosal delivery, the ease of design, and the recent clinical successes with DNA vaccines suggests that this approach is on the precipice of redefining the field of vaccinology.

**Disclosure of potential conflicts of interest**

James A. Williams has an equity interest in Nature Technology Corporation. Due to this relationship with Nature Technology Corporation, the author acknowledges that there is a potential conflict of interest inherent in the publication of this manuscript and assert that an effort to reduce or eliminate that conflict has been made where possible.

**Funding**

John J. Suschak and Connie S. Schmaljohn would like to acknowledge funding from the Joint Science and Technology Office for Chemical and Biological Defense of the Defense Threat and Reduction Agency. The opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army.

**References**

1. Galvin TA, Muller J, Khan AS. Effect of different promoters on immune responses elicited by HIV-1 gag/env multigenic DNA vaccine in Macaca mulatta and Macaca nemestrina. Vaccine 2000; 18:2566-83; PMID:10775791; https://doi.org/10.1016/S0264-410X(99)00569-1
2. Huang MT, Gorman CM. Intervening sequences increase efficiency of RNA 3′ processing and accumulation of cytoplasmic RNA. Nucleic Acids Res 1990; 18:937-47; PMID:1690394; https://doi.org/10.1093/nar/18.4.937
3. Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines 2016; 15:313-29; PMID:26707950
4. Goulder PJ, Rowland-Jones SL, McMichael AJ, Walker BD. Anti-HIV cellular immunity: recent advances towards vaccine design. AIDS 1999; 13 Suppl A:S121-36. PMID:10885771
5. Giri M, Ugen KE, Weiner DB. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 2004; 17:370-89; PMID:15084506; https://doi.org/10.1128/CMR.17.2.370-389.2004
6. Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoevity T, Carucci DJ, Hedstrom RC, Rahardjo N, Gay T, Hobart P, et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A 2001; 98:10817-22; PMID:11526203; https://doi.org/10.1073/pnas.181123498
7. Hollier K, Chen Y, Wang S, Wu H, Mondal A, Clegg N, Lu S, Dest A. The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination. Hum Vaccin Immunother 2014; 10:1985-92; PMID:25424808; https://doi.org/10.4161/hv.28659
8. Wolff JA, Malone RW, Williams P, Chong W, Acadi G, Jani A and Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8; PMID:1690918; https://doi.org/10.1126/science.1690918
9. Ulmer JB, Donnelly J, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9; PMID:8456302; https://doi.org/10.1126/science.8456302
10. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26:3947-57; PMID:18724414; https://doi.org/10.1016/j.vaccine.2007.12.060 10.1016/j.vaccine.2007.12.024
11. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with a polynucleotide immunomodulatory molecular adjuvant plasmid. J Infect Dis 1996; 173:314-20; PMID:8568291; https://doi.org/10.1086/517314
12. Fuller DH, Haynes JR. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine.
AIDS Res Hum Retroviruses 1994; 10:1433-41; PMID:788198; https://doi.org/10.1089/aid.1994.10.1433

[13] Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, Livingston BD, Schmaljohn CS. A DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clin Vaccine Immunol 2011; 18:707-16; PMID:21450977; https://doi.org/10.1128/CVI.00300-11

[14] Dupuy LC, Richards MJ, Reed DS, Schmaljohn CS. Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates. Vaccine 2010; 28:7345-50; PMID:20851089; https://doi.org/10.1016/j.vaccine.2010.09.005

[15] Grant-Klein RJ, Altamura LA, Badger CV, Bounds CE, Van Deusen NM, Kwials SA, Vu HA, Warfield KL, Hooper JW, Hannaman D, et al. Cod-on-optimized flavivirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Hum Vaccines Immunotherapeutics 2015; 11:1991-2004; https://doi.org/10.1080/21655515.2015.1039757

[16] Grant-Klein RJ, Van Deusen NM, Badger CV, Hannaman D, Dupuy LC, Schmaljohn CS. A multiagent flavivirus DNA vaccine delivered by intramuscular electroporation completely protects mice from Ebola and Marburg virus challenge. Hum Vaccin Immunother 2012; 8:1703-6; PMID:22922764; https://doi.org/10.4161/hvi.21873

[17] Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et al. Immunotherapy against HPV16/18 generates potent Th1 and cytotoxic cellular immune responses. Sci Transl Med 2012; 4:155ra138; PMID:23052295; https://doi.org/10.1126/scitranslmed.3004414

[18] Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011; 6:e19252; PMID:21603651; https://doi.org/10.1371/journal.pone.0019252

[19] Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Vasan S, Bailer R, Pearce MB, Tumpey TM, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine mixture administered at low doses. Vaccine 2011; 29:3550-6; PMID:21628480; https://doi.org/10.1016/j.vaccine.2011.06.044

[20] Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, Lee CW, Kim S, Woo JW, Park KS, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. J Med Virol 2014; 86:128-36; PMID:24440303; https://doi.org/10.1002/jmv.24440

[21] Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, Patterson N, Ferrari M, Kaslow DC, Carucci DJ, Richie TL, et al. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 2006; 24:2192-7

[22] Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, Patterson N, Ferrari M, Kaslow DC, Carucci DJ, Richie TL, et al. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 2006; 24:2192-7

[23] Boccazzi MG, Tanzella G, Manzetti MP. Phase I clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010; 28:3055-65; PMID:19879998; https://doi.org/10.1016/j.vaccine.2009.10.044

[24] Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010; 28:3055-65; PMID:19879998; https://doi.org/10.1016/j.vaccine.2009.10.044

[25] Liu J, Wu J, Wang B, Zeng S, Qi F, Lu C, Kimura Y, Liu B. Oral vaccination with a liposome-encapsulated influenza DNA vaccine protects mice against respiratory infection. J Med Virol 2014; 86:886-94; PMID:24122866; https://doi.org/10.1002/jmv.23768

[26] Ma J, Wang H, Zheng X, Xue X, Wang B, Wu H, Zhang K, Fan S, Wang T, Li N, et al. CpG/Poly (I:C) mixed adjuvant priming enhances antigen specific antibody titers and maintains Th1 type immune response in rabbits to a malaria DNA vaccine. Vaccine 2014; 19:3778-86; PMID:21395213; https://doi.org/10.1016/j.vaccine.2014.01.002

[27] Chen L, Zhu J, Li Y, Li J, Yang X. Enhanced nasal mucosal delivery and immunogenicity of anti-caries DNA vaccine through incorporation of anionic liposomes in chitosan/ DNA complexes. PLoS One 2013; 8:e71953; PMID:23977186; https://doi.org/10.1371/journal.pone.0071953
[39] Basarker A, Devinevi D, Palaniappan R, Singh J. Preparation, character- ization, cytotoxicity and transection efficiency of poly(DL- lactic-co-glycolide) and poly(DL-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA. Int J Pharm 2007; 343:247-54; PMID:1761054; https://doi.org/10.1016/j.ijpharm.2007.05.023

[40] Mok H, Park TG. Direct plasmid DNA encapsulation within PLGA nanoparticles by microencapsulation in oil-in-water emulsion method. Eur J Pharm Biophys 2008; 68:105-11; PMID:17870446; https://doi.org/10.1016/j.ejpb.2007.04.022

[41] Hao T, McKeever U, Hedley ML. Biological potency of microsphere encapsulated plasmid DNA. J Control Release 2000; 69:249-59; PMID:11064132; https://doi.org/10.1016/S0168-3659(00)00304-7

[42] Singh M, Briones M, Ott G, O’Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A 2000; 97:811-6; PMID:10639162; https://doi.org/10.1073/pnas.97.2.811

[43] Aral C, Akbuga J. Preparation and in vitro transfection efficiency of chitosan microspheres containing plasmid DNA poly(L-lysine) complexes. J Pharm Sci 2003; 63:321-6; PMID:14738712

[44] Alexakis T, Boadi DK, Quong D, Groboillot A, O’Regan J, Bruneau B, Liu H, Srivastava I, Megede J, Kazzaz A, Herrmann JE, Chen SC, Jones DH, Tinsley-Bown A, Fynan EF, Alexakis T, Boadi DK, Quong D, Groboillot A, O’Regan J, Bruneau B, Liu H, Srivastava I, Megede J, Kazzaz A, Herrmann JE, Chen SC, Jones DH, Tinsley-Bown A, Fynan EF, Aral C, Akbuga J. Preparation and in vitro transfection efficiency of chitosan microspheres containing plasmid DNA poly(L-lysine) complexes. J Pharm Sci 2003; 63:321-6; PMID:14738712

[45] Miguel M, McGlade JA, Apostolopoulos V, Plebanski M. Poly-L-lysine-coated nanoparticles for controlled delivery of plasmid DNA. Vaccine 2004; 22:3092-7; PMID:15297060; https://doi.org/10.1016/j.vaccine.2004.01.065

[46] Minigo G, Scholzen A, Tang CK, Hanley JC, Kalkanidis M, Pieters GA, Apostolopoulos V, Plebanski M, Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine 2007; 25:1316-27; PMID:17052812; https://doi.org/10.1016/j.vaccine.2006.09.086

[47] Hao T, McKeever U, Hedley ML. Biological potency of microsphere encapsulated plasmid DNA. J Control Release 2000; 69:249-59; PMID:11064132; https://doi.org/10.1016/S0168-3659(00)00304-7

[48] Coban C, Ishii KJ, Gursel M, Klimman DM, Kumar N. Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J Leukoc Biol 2005; 78:647-55; PMID:15961575; https://doi.org/10.1189/jlb.1104627

[49] Abdulhaq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008; 42:219-32; PMID:19066740; https://doi.org/10.1007/s12026-008-0807-3

[50] Laddy DJ, Weiner DJ. From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol 2006; 25:99-123; PMID:16818367; https://doi.org/10.1080/026441099314441

[51] Hu H, Tao L, Wang Y, Chen L, Yang J, Wang H. Enhancing immune responses against SARS-CoV nucleocapsid DNA vaccine by electroporation and co-delivered genetic adjuvants. J Interferon Cytokine Res 1999; 19:77-84; PMID:10048771; https://doi.org/10.1089/107999099314441

[52] Wang F, He XW, Jiang L, Ren D, He Y, Li DA, Sun SH. Enhanced immunogenicity of microencapsulated multipeptide DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in rhesus macaques by using a priming-boosting regimen with recombimant proteins. J Virol 2005; 79:8189-200; PMID:15956564; https://doi.org/10.1128/JVI.79.13.8189-8200.2005

[53] Wang F, He XW, Jiang L, Ren D, He Y, Li DA, Sun SH. Enhanced immunogenicity of microencapsulated multipeptide DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice. Vaccine 2006; 24:2017-26; PMID:16414158; https://doi.org/10.1016/j.vaccine.2005.11.042

[54] Kojima Y, Xin QK, Ooki T, Hamajima K, Oikawa T, Shinoda K, Oraki T, Hoshino Y, Jounai N, Nakazawa M, Klimman D, et al. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 2002; 20:2857-65; PMID:12126895; https://doi.org/10.1016/S0264-410X(02)00238-4

[55] Coban C, Ishii KJ, Gursel M, Klimman DM, Kumar N. Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J Leukoc Biol 2005; 78:647-55; PMID:15961575; https://doi.org/10.1189/jlb.1104627

[56] Abdulhaq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008; 42:219-32; PMID:19066740; https://doi.org/10.1007/s12026-008-0807-3

[57] Laddy DJ, Weiner DJ. From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol 2006; 25:99-123; PMID:16818367; https://doi.org/10.1080/026441099314441

[58] Coban C, Ishii KJ, Gursel M, Klimman DM, Kumar N. Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J Leukoc Biol 2005; 78:647-55; PMID:15961575; https://doi.org/10.1189/jlb.1104627

[59] Abdulhaq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008; 42:219-32; PMID:19066740; https://doi.org/10.1007/s12026-008-0807-3

[60] Laddy DJ, Weiner DJ. From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol 2006; 25:99-123; PMID:16818367; https://doi.org/10.1080/026441099314441

[61] Hu H, Tao L, Wang Y, Chen L, Yang J, Wang H. Enhancing immune responses against SARS-CoV nucleocapsid DNA vaccine by electroporation and co-delivered genetic adjuvants. J Interferon Cytokine Res 1999; 19:77-84; PMID:10048771; https://doi.org/10.1089/107999099314441

[62] Barouch DH, Truitt DM, Levin NL. Expression kinetics of the interleukin-2/immunglobulin (IL-2-lg) plasmid cytokine adjuvant. Vaccine 2004; 22:3092-7; PMID:15297060; https://doi.org/10.1016/j.vaccine.2004.01.065

[63] Henke A, Rohlund N, Zell R, Wuttler P. Co-expression of interleukin-2 by a bicistronic plasmid increases the efficacy of DNA immunization to prevent influenza virus infections. Interivirology 2006; 49:249-52; PMID:16601357; https://doi.org/10.1111/j.1365-2076.2005.00287.x

[64] Hu H, Tao L, Wang Y, Chen L, Yang J, Wang H. Enhancing immune responses against SARS-CoV nuclecapsid DNA vaccine by co-inoculating interleukin-2 expressing vector in mice. Biotechnol Lett 2009; 31:1685-93; PMID:19579009; https://doi.org/10.1007/s10529-009-0061-y

[65] Qin Y, Tian H, Wang G, Lin C, Li Y. A BCR/ABL-hIL-2 DNA vaccine enhances the immune responses in BALB/c mice. Biomed Res Int 2013; 2013:136492; PMID:23841051; https://doi.org/10.1155/2013/136492

[66] McGill J, Van Rooijen N, Legge KL. IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival.
during influenza virus infection. J Exp Med 2010; 207:521-34; PMID:20212069; https://doi.org/10.1084/jem.20091711

[70] Schluns KS, Williams K, Ma A, Zheng X, Lefrancois L. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol 2002; 168:4827-31; PMID:11994430; https://doi.org/10.4049/jimmunol.168.10.4827

[71] Yajima T, Yoshida K, Nakazato K, Kumabe S, Koyasu S, Sad S, Shen H, Kuvano H, Yoshikai Y. IL-15 regulates CD8+ T cell contraction during primary infection. J Immunol 2006; 176:507-15; PMID:16365444; https://doi.org/10.4049/jimmunol.176.1.507

[72] Combe CL, Moretto MM, Schwartzman JD, Gigley JP, Bzik DJ, Khan IA. Lack of IL-15 results in the suboptimal priming of CD4+ T cell response against an intracellular parasite. Proc Natl Acad Sci U S A 2006; 103:6635-40; PMID:16614074; https://doi.org/10.1073/pnas.0506180103

[73] Ruckert R, Brandt K, Bulanova E, Mirghomizadeh F, Paus R, Schluns KS, Williams K, Ma A, Zheng XX, Lefrancois L. Cutting Trinchieri G. Interleukin-12: a cytokine at the interface of T cells. Gene Ther 2015; 22:76-86; PMID:25273353; https://doi.org/10.1038/gt.2014.84

[74] Chen J, Li ZY, Huang SY, Petersen E, Song HQ, Chen J, Li ZY, Huang SY, Petersen E, Song HQ, Zhou DH, Zhu XQ. Ruckert R, Brandt K, Bulanova E, Mirghomizadeh F, Paus R, Schluns KS, Williams K, Ma A, Zheng XX, Lefrancois L. Cutting syndrome against simian/human immunode10.1038/jem.170.3.827

[75] Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70:83-243; PMID:9755338

[76] Hunter CA, Chizzone R, Remington JS. IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. J Immunol 1995; 155:4347-54; PMID:7594594

[77] Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G. Mechanisms of IFN-gamma production by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992; 148:92-8; PMID:1345792

[78] Manetti R, Gerosa F, Giudizi MG, Biagiotti R, Parronchi P, Piccinini MP, Sampognaro S, Maggi E, Romagnani S, Trinchieri G, et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 1994; 179:1273-83; PMID:9708322; https://doi.org/10.1083/jem.179.4.1273

[79] Kalams SA, Parker SD, Elizaqita M, Betch B, Edupchard S, Hural J, De Rosa S, Carter DK, Rybczynk F, Frank I, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013; 208:818-29; PMID:23840403; https://doi.org/10.1093/infdis/jit236

[80] Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon M, Boyer JD, Wang B, Weiner DB. Development of a multicomponent candidate vaccine for HIV-1. Vaccine 1997; 15:879-83; PMID:9234538; https://doi.org/10.1016/s0264-410x(06)00260-5

[81] Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, Betts MR, Dragha-Akli R, Weiner DB. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008; 26:3112-20; PMID:18430495; https://doi.org/10.1016/j.vaccine.2008.02.036

[82] Boyer JD, Robinson TM, Kutzler MA, Parkinson R, Calarota SA, Siddhu MK, Muthumana K, Lewis M, Pavlikas G, Felber B, et al. DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 cell immune responses in cynomolgus macaques. J Med Primatol 2005; 34:262-70; PMID:16128291; https://doi.org/10.1111/j.1600-0684.2005.00124.x

[83] Chong SY, Egan MA, Kutzler MA, Megatti S, Masood A, Roopchard V, Garcia-Hand D, Montefiori DC, Quiroz J, Rosati M, et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIV gag plasmid DNA vaccine and alter disease progression following SHIV (89.6P) challenge in rhesus macaques. Vaccine 2005; 23:4627-40; PMID:16128291; https://doi.org/10.1111/j.1600-0684.2005.00124.x

[84] Robinson TM, Siddhu MK, Pavlikas GN, Felber BK, Silvers P, Lewis MG, Eldridge J, Weiner DB, Boyer JD. Macaques co-immunized with SIV gag/pol-HIV env and IL-12 plasmid have increased cellular responses. J Med Primatol 2006; 35:267-76; PMID:16128291; https://doi.org/10.1111/j.1600-0684.2006.00124.x

[85] Bagley KC, Schwartz JA, Andersen H, Eldridge JH, Xu R, Ota-Seltik A, Geltz Jr, Halford WP, Fouts TR. An interleukin 12 adjuvanted herpes simplex virus 2 DNA vaccine is more protective than a glycoprotein D subunit vaccine in a high-dose murine challenge model. Viral Immunol. 2017; 30:178-95; PMID:28085634; https://doi.org/10.1089/vim.2016.0136

[86] Morrow MP, Yan J, Pankhong P, Ferraro B, Lewis MG, Khan AS, Sardesai NY, Weiner DB. Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin Vaccine Immunol 2010; 17:1493-9; https://doi.org/10.1128/CVI.00181-09

[87] Bhaumik S, Basu R, Sen S, Naskar K, Roy S, KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 2009; 27:1306-16; PMID:19182074; https://doi.org/10.1016/j.vaccine.2008.12.053

[88] Yamanaka H, Horigi T, Yang X, Golden S, Bosio CM, Cizk A, Becker T, Maddaloni M, Pascual DW. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection
against pneumonic plague. Infect Immun 2008; 76:4564-73; PMID:18694965; https://doi.org/10.1128/IAI.00581-08

[97] Schadeck EB, Sidhu M, Egan MA, Chong SY, Placente P, Masood A, Garcia-Hand D, Cappello S, Roopchand V, Megati S, et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIV gag plasmid DNA vaccine in rhesus macaques. Vaccine 2006; 24:4677-87; PMID:16288822; https://doi.org/10.1016/j.vaccine.2005.10.035

[98] Halwani R, Boyer JD, Yassin-Diab B, Haddad EK, Robinson TM, Kumar S, Parkinson R, Wu L, Sidhu MK, Phillipson-Weiner R, et al. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol 2008; 180:7697-79; PMID:18523260; https://doi.org/10.4049/jimmunol.180.12.7699

[99] Li J, Valentin A, Kulkarni V, Rosati M, Beach RK, Alicea C, Walker BD. Levels of human immunodeciency virus vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 2013; 31:3747-55; PMID:23624057; https://doi.org/10.1016/j.vaccine.2013.04.037

[100] Cha E, Daud A. Plasmid IL-12 electroporation in melanoma. Hum Vaccin Immunother 2012; 8:1734-47; PMID:23151447; https://doi.org/10.4161/hv.22573

[101] Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, Santana VC, Almeida RR, Ribeiro SP, Ferreira LC, Kalil J, Rosa DS, Ahlers JD, Belyakov IM, Terabe M, Koka R, Donaldson DD, Weiss WR, Ishii KJ, Hedstrom RC, Sedegah M, Ichino M, Barnhart Cunha-Neto E. Co-administration of plasmid-encoded granulocyte-macrophage colony-stimulating factor enhances human immunodeficiency virus-1 DNA vaccine-induced polyfunctional CD4+ T-cell responses. Mem Inst Oswaldo Cruz 2015; 110:1010-6; PMID:26602876

[102] Chen H, Gao N, Wu J, Zheng X, Li J, Fan D, An J. Variable effects of the co-administration of a GM-CSF-expressing plasmid on the immune response to flavivirus DNA vaccines in mice. Immunol Lett 2014; 162:140-8; PMID:25128840

[103] Kumar S, Villinger F, Oakley M, Aguilar JC, Jones TR, Hedstrom RC, Gowda K, Chute J, Stowers A, Kasilow DC, et al. A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immune-stimulatory effects of granulocyte macrophage-colony stimulating factor. Immunol Lett 2002; 81:13-24; PMID:11841841

[104] Cassaday RD, Sondel PM, King DM, Macklin MD, Gan J, Warner TF, Zuleger CL, Bridges AJ, Schalch HG, Kim KM, et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res 2007; 13:540-9; PMID:17255276; https://doi.org/10.1158/1078-0432.CCR-06-2039

[105] Barouch DH, Letvin NL, Seder RA. The role of cytokine DNA as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 2004; 202:266-74; PMID:15546399; https://doi.org/10.1111/j.1600-065X.2004.00200.x

[106] Wan C, Yi L, Yang Z, Jang Y, Shao H, Zhang C, Pan Z. The Toll-like receptor adaptor molecule TRIF enhances DNA vaccination against classical swine fever. Vet Immunol Immunopathol 2010; 137:47-53; PMID:20466439; https://doi.org/10.1016/j.vetimm.2010.04.008

[107] Takeshi F, Tanaka T, Matsuuda T, Tozuka M, Kobiyama Y, Saha S, Matsu K, Ishii KJ, Coban C, Akira S, et al. T–like receptor adaptor molecules enhance DNA–raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol 2006; 80:6218-24; PMID:16775309; https://doi.org/10.1128/JVI.00121-06

[108] Liniger M, Summerfeldt A, Ruggli N. MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens. PLoS One 2012; 7:e49952; PMID:23227156; https://doi.org/10.1371/journal.pone.0049952

[109] Luke JM, Simon GG, Soderholm J, Errett JS, August JT, Gale M Jr., Hodgson CP, Williams JA. Coexpressed RIG-1 agonist enhances humoral immune response to influenza virus DNA vaccine. J Virol 2011; 85:1370-83; PMID:21106745; https://doi.org/10.1128/JVI.01250-10

[110] Yang B, Yang A, Peng S, Pang X, Roden RB, Wu TC, Hung CF. Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination. Cell Biosci 2015; 5:53; PMID:26113972; https://doi.org/10.1186/s13578-015-0025-y

[111] Massa S, Paolini F, Spano L, Francoini R, Venuiti A. Mutants of plant genes for developing cancer vaccines. Hum Vaccin 2011; 7: Suppl:147-55; PMID:21266841; https://doi.org/10.4161/hv.7.0.14577

[112] Kim JW, Hung CF, Jiang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PJ, Lin CT, Boyd DA, et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 2004; 11:1011-8; PMID:14985791; https://doi.org/10.1016/j.2004.02000.x

[113] Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ, Harper LG, Griffiths TG, 2nd, Niu Z, Denisova L, Follmer TT, et al. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 2000; 43:273-81; PMID:11251382; https://doi.org/10.1159/000053994

[114] Nichols WW, Ledwith BJ, Manam SV, Troilo PJ. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci 1995; 772:30-9; PMID:8546411; https://doi.org/10.1111/j.1749-6632.1995.tb44729.x

[115] Sorensen SJ, Bailey M, Hansen LH, Kroer N, Wuerzt S. Studying plasmid horizontal transfer in situ: a critical review. Nat Rev Microbiol 2005; 3:700-10; PMID:16138098; https://doi.org/10.1038/nrmicro1232

[116] Oliveira PH, Mairhofer J. Marker-free plasmids for biotechnological applications - implications and perspectives. Trends Biotechnol
Zevini A, Olagnier D, Hiscott J. Crosstalk between cytoplasmic RIG-I and STING sensing pathways. Trends Immunol. 2017; 38:194-205; PMID:28073693; https://doi.org/10.1016/j.it.2016.12.004

Suschak JJ, Wang S, Fitzgerald KA, Lu S. A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines. J Immunol 2016; 196:310-6; PMID:26590319; https://doi.org/10.4049/jimmunol.1501836

Borggren M, Nielsen J, Bragstad K, Karlsson I, Krog JS, Wilm A, Nielsen J, Bragstad K, Karlsson I, Krog JS, Wil...